Pharming Group NV
F:PHGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharming Group NV
F:PHGN
|
NL |
|
I
|
Infratil Ltd
ASX:IFT
|
NZ |
|
iQ International AG
F:IQL
|
CH |
|
J
|
JAFCO Group Co Ltd
F:JAF
|
JP |
|
National Australia Bank Ltd
F:NAL0
|
AU |
|
C
|
Carlisle Companies Inc
XMUN:CLE
|
US |
|
H
|
Heidelberg Pharma AG
XBER:HPHA
|
DE |
|
C
|
Clearside Biomedical Inc
F:CLM
|
US |
|
Q2 Metals Corp
F:458
|
CA |
|
P
|
PDF Solutions Inc
F:PD9
|
US |
Wall St Price Targets
PHGN Price Targets Summary
Pharming Group NV
According to Wall Street analysts, the average 1-year price target for PHGN is 2.2165 EUR with a low forecast of 1.7855 EUR and a high forecast of 2.6812 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PHGN's stock price target?
Price Target
2.2165
EUR
According to Wall Street analysts, the average 1-year price target for PHGN is 2.2165 EUR with a low forecast of 1.7855 EUR and a high forecast of 2.6812 EUR.
What is the Revenue forecast for Pharming Group NV?
Projected CAGR
20%
Over the last 14 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 5 years is 20%.
What is the Gross Profit forecast for Pharming Group NV?
Projected CAGR
0%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 49%. The projected CAGR for the next 3 years is 0%.
What is the Operating Income forecast for Pharming Group NV?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 5 years is 36%.
What is the Pre-Tax Income forecast for Pharming Group NV?
Projected CAGR
53%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 53%.
What is the Net Income forecast for Pharming Group NV?
Projected CAGR
112%
The compound annual growth rate for Net Income over the next 5 years is 112%.
